Back to trial detailsIntake questionnaire
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Applying to Georgetown University Medical Cener (GUMC) · Washington D.C., District of Columbia
Answer a few short questions to share with the research team.
0 of 4 answered